Compare ADMA Biologics Inc (ADMA) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Roundhill Magnificent Seven ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Roundhill Magnificent Seven ETF trades at $65.7. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MAGS | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $70.94 |
52-Week Low | $7.60 | $55.02 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MAGS (Roundhill Magnificent Seven ETF) trades at $66.28, up 1.81% on the day, with a bullish technical signal driven by moving averages. The ETF holds seven mega-cap tech stocks equally weighted, rebalanced quarterly. Recent news highlights AI-driven market broadening and MAGS's historical outperformance, though 2026 has seen volatility with a drop from YTD highs near $71. RSI_6 at 72.47 suggests short-term overbought conditions.
Outlook: MAGS offers concentrated exposure to leading tech innovators with strong long-term growth potential, but faces risks from high concentration, valuation concerns, and macroeconomic sensitivity. Near-term resistance at $67–68 may cap gains unless earnings momentum accelerates. Diversification benefits are limited due to single-sector focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
